

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Heart, Lung, And Blood Institute; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<https://videocast.nih.gov/watch/d3614358-26f0-11f1-9f14-124f0a52e769>).

*Name of Committee:* Sickle Cell Disease Advisory Committee (SCDAC).

*Date:* May 26, 2026.

*Time:* 11:00 a.m. to 4:00 p.m.

*Agenda:* Nutrition in Sickle Cell Disease.

*Address:* National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Julie A Panepinto, MD, MSPH, Professor, DFO/Executive Secretary, SCDAC, Division of Blood Diseases and Resources, 6701 Rockledge Drive, Suite 9166,

Bethesda, MD 20892, (301) 435-0080, [Julie.panepinto@nih.gov](mailto:Julie.panepinto@nih.gov).

Registration is not required to attend the open portion of this meeting. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <https://www.nhlbi.nih.gov/advisory-and-peer-review-committees/nhlbi-sickle-cell-disease-advisory-committee>, where an agenda and any additional information for the meeting will be posted when available.

Dated: April 9, 2026.

**Denise M. Santeufemio,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-07150 Filed 4-13-26; 8:45 am]

**BILLING CODE 4140-01-P**

**ACTION:** Notice.

**SUMMARY:** The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Septune, Inc., located in San Juan, Puerto Rico, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development May 14, 2026 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Michael Shmilovich, Esq., MS, CLP Acting Director, phone number 301-435-5019 or [shmilovm@nih.gov](mailto:shmilovm@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective license to Septune, Inc.:

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of Exclusive Patent License: Catheter-Based Myotomy Devices And Systems**

**AGENCY:** National Institutes of Health.

NIH Ref No.	Patent No. or application No.	Filing date	Title
E-194-2025-0-US-01 .....	63/890,784	September 30, 2025 .....	Electrosurgical Myotomy Catheter System.
E-166-2022-0-US-01 .....	63/383,012	November 9, 2022 .....	Myotomy Catheter System And Methods For A Myotomy Catheter System.
E-166-2022-0-PC-01 .....	PCT/US2023/079114	November 8, 2023 .....	Myotomy Catheter System And Methods For A Myotomy Catheter System.
E-166-2022-0-US-02 .....	19/127,710	November 8, 2023 .....	Myotomy Catheter System And Methods For A Myotomy Catheter System.
E-166-2022-0-EP-01 .....	23821091.8	November 8, 2023 .....	Myotomy Catheter System And Methods For A Myotomy Catheter System.

The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive patent license territory may be worldwide and in a field of use limited to catheter-based myocardial myotomy systems for the treatment of cardiovascular disease.

The invention described in E-194-2025 for which we currently have a provisional patent application covers a variable-depth electrosurgical myotomy catheter system configured to perform a longitudinal endomyocardial myotomy, also referred to as septal scoring along the midline endocardium (SESAME). The catheter system is configured to

slice the "septal hump" causing symptomatic left ventricular outflow tract obstruction in hypertrophic cardiomyopathy (HCM), a common congenital heart disease in adults and children. The system may have further applications in creating space to allow non-surgical transcatheter mitral valve implantation (TMVR), which excludes more than half of TMVR candidates, and potentially reduces left ventricular stiffness causing heart failure with preserved ejection fraction (HFpEF), a widely prevalent disease.

The invention described in E-166-2022, for which we now have pending national stage applications in the US

and Europe, pertains to a controlled-depth myotomy catheter system configured to perform a longitudinal endomyocardial myotomy (also referred to as septal scoring along the midline endocardium (SESAME)) precisely and reproducibly with less operator skill than previous SESAME procedures, less reliance on image guidance, and lowered procedure times. SESAME is conventionally accomplished by navigating a 0.014" guidewire under x-ray fluoroscopy and ultrasound guidance via a retrograde transaortic guiding catheter through the interventricular septum. A straight rigid engagement guidewire engages the basal